Bone Biologics (BBLG) Net Income towards Common Stockholders (2010 - 2025)
Bone Biologics (BBLG) reported Net Income towards Common Stockholders of -$684643.0 for Q4 2025, up 55.01% year-over-year from -$441681.1 in Q4 2024, and down 2.69% quarter-over-quarter from -$666737.0 in Q3 2025.
Bone Biologics (BBLG) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Bone Biologics (BBLG) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$684643.0 in Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$684643.0, up 55.01% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.1 million (up 57.8% YoY), and the FY2025 annual result was -$3.1 million, up 57.56% from the prior year.
- Net Income towards Common Stockholders slipped to -$684643.0 in Q4 2025 per BBLG's latest filing, from -$666737.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$176137.0 in Q4 2021 and troughed at -$4.2 million in Q3 2024.
- A 5-year average of -$1.3 million and a median of -$848899.5 in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 630.73% in 2022, then soared 83.95% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$176137.0 in 2021, then tumbled by 630.73% to -$1.3 million in 2022, then declined by 20.42% to -$1.5 million in 2023, then climbed by 1.82% to -$1.5 million in 2024, then surged by 55.01% to -$684643.0 in 2025.
- Business Quant data shows BBLG's Net Income towards Common Stockholders at -$684643.0 in Q4 2025, -$666737.0 in Q3 2025, and -$741421.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | -684,643.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -684,643.00 |
| Sep 30, 2025 | -666,737.00 |
| Jun 30, 2025 | -741,421.00 |
| Mar 31, 2025 | -1.02 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Sep 30, 2024 | -4.15 Mn |
| Jun 30, 2024 | -794,518.00 |
| Mar 31, 2024 | -903,281.00 |
| Dec 31, 2023 | -1.55 Mn |
| Sep 30, 2023 | -1.92 Mn |
| Jun 30, 2023 | -3.04 Mn |
| Mar 31, 2023 | -3.15 Mn |
| Dec 31, 2022 | -1.29 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -437,827.00 |
| Mar 31, 2022 | -689,499.00 |
| Dec 31, 2021 | -176,137.00 |
| Sep 30, 2021 | -509,303.00 |
| Jun 30, 2021 | -491,898.00 |
| Mar 31, 2021 | -431,747.00 |